Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Methods for Neuroscience Drug Development: Guidance on Standardization of the Process for Defining Clinical Outcome Strategies in Clinical Trials.
Zaragoza Domingo S, Alonso J, Ferrer M, Acosta MT, Alphs L, Annas P, Balabanov P, Berger AK, Bishop KI, Butlen-Ducuing F, Dorffner G, Edgar C, de Gracia Blanco M, Harel B, Harrison J, Horan WP, Jaeger J, Kottner J, Pinkham A, Tinoco D, Vance M, Yavorsky C. Zaragoza Domingo S, et al. Among authors: balabanov p. Eur Neuropsychopharmacol. 2024 Jun;83:32-42. doi: 10.1016/j.euroneuro.2024.02.009. Epub 2024 Apr 4. Eur Neuropsychopharmacol. 2024. PMID: 38579661 Free article. Review.
Applying the EU regulatory framework for the clinical use of psychedelics.
Butlen-Ducuing F, Silva F, Silva I, Balabanov P, Thirstrup S. Butlen-Ducuing F, et al. Among authors: balabanov p. Lancet Psychiatry. 2025 Jan;12(1):7-9. doi: 10.1016/S2215-0366(24)00203-7. Epub 2024 Jul 4. Lancet Psychiatry. 2025. PMID: 38972323 No abstract available.
The therapeutic potential of psychedelics: the European regulatory perspective.
Butlen-Ducuing F, McCulloch DE, Haberkamp M, Mattila T, Bałkowiec-Iskra E, Aislaitner G, Balabanov P, Lundberg J, Stenbæk DS, Elferink A, Knudsen GM, Thirstrup S. Butlen-Ducuing F, et al. Among authors: balabanov p. Lancet. 2023 Mar 4;401(10378):714-716. doi: 10.1016/S0140-6736(23)00264-7. Epub 2023 Feb 10. Lancet. 2023. PMID: 36780909 No abstract available.
Translational and regulatory challenges for exon skipping therapies.
Aartsma-Rus A, Ferlini A, Goemans N, Pasmooij AM, Wells DJ, Bushby K, Vroom E, Balabanov P. Aartsma-Rus A, et al. Among authors: balabanov p. Hum Gene Ther. 2014 Oct;25(10):885-92. doi: 10.1089/hum.2014.086. Hum Gene Ther. 2014. PMID: 25184444 Review.
Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy.
Straub V, Balabanov P, Bushby K, Ensini M, Goemans N, De Luca A, Pereda A, Hemmings R, Campion G, Kaye E, Arechavala-Gomeza V, Goyenvalle A, Niks E, Veldhuizen O, Furlong P, Stoyanova-Beninska V, Wood MJ, Johnson A, Mercuri E, Muntoni F, Sepodes B, Haas M, Vroom E, Aartsma-Rus A. Straub V, et al. Among authors: balabanov p. Lancet Neurol. 2016 Jul;15(8):882-890. doi: 10.1016/S1474-4422(16)30035-7. Lancet Neurol. 2016. PMID: 27302365 Review.
23 results